Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α

Longhe Yang1,2,*, Long Li1,3,*, Ling Chen1, Yanting Li1, Huixia Chen1, Yuhang Li1, Guangnian Ji1, Donghai Lin3, Zuguo Liu1 & Yan Qiu1

Pharmacological blockade of N-acylethanolamine acid amidase (NAAA) activity is an available approach for inflammation and pain control through restoring the ability of endogenous PEA. But the recently reported NAAA inhibitors suffer from the chemical and biological unstable properties, which restrict functions of NAAA inhibition in vivo. It is still unrevealed whether systematic inhibition of NAAA could modulate PEA-mediated pain signalings. Here we reported an oxazolidinone imide compound 3-(6-phenylhexanoyl) oxazolidin-2-one (F96), which potently and selectively inhibited NAAA activity (IC50 = 270 nM). Intraperitoneal (i.p.) injection of F96 (3–30 mg/kg) dose-dependently reduced ear edema and restored PEA levels of ear tissues in 12-O-Tetradecanoylphorbol-13-acetate (TPA) induced ear edema models. Furthermore, F96 inhibited acetic acid-induced writhing and increased spared nerve injury induced tactile allodynia thresholds in a dose-dependent manner. Pharmacological effects of F96 (10 mg/kg, i.p.) on various animal models were abolished in PPAR-α−/− mice, and were prevented by PPAR-α antagonist MK886 but not by cannabinoid receptor type 1 (CB1) antagonist Rimonabant nor cannabinoid receptor type 2 (CB2) antagonist SR144528. Zebrafish embryos experiments showed better security and lower toxicity for F96 than ibuprofen. These results revealed that F96 might be useful in treating inflammatory and neuropathic pain by NAAA inhibition depending on PPAR-α receptors.

Endogenous fatty acid ethanolamides (FAEs) play important roles in modulation of a wide range of physiological and pathological processes, especially for inflammatory and neuropathic pain1–2. Increasing FAEs as anandamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) in vivo effectively elicit anti-inflammation and anti-nociception in various animal models through ‘Nature’s own mechanisms’3–5. These lipid messengers are supposed to be produced and degraded by enzymes in mammalian cells to maintain cellular homeostasis, which are different with the classic neurotransmitters stored in vesicles at all time6. Among them, PEA is approved as ‘Dietary Foods for Special Medical Purposes’ to treat chronic pain, which is commercially available in Italy and several other European countries. PEA is also widely studied in recent clinical trials, such as temporomandibular joint inflammatory pain7 and various chronic pain8–9, but its analgesic effects is far from powerful10.

1Medical College, Xiamen University, Xiamen, Fujian 361005, P. R. China. 2Engineering Research Center of Marine Biological Resource Comprehensive Utilization, Third Institute of Oceanography, State Oceanic Administration, Xiamen, Fujian 361005, P. R. China. 3Department of Chemistry and The Key Laboratory for Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian 361005, P. R. China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to Z.G.L. (email: zuguoliu@xmu.edu.cn) or Y.Q. (email: yanqiu@xmu.edu.cn)
It is revealed that PEA is biosynthesized from N-palmitoyl-phosphatidyl-ethanolamine to exert analgesic and anti-inflammatory effects, which are mainly attributed to activation of nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α). While, PEA can also be observed to be reduced obviously during pathological conditions as in rat granuloma tissue, carrageenin induced mice paw edema skin, and sciatic nerve tissue after chronic constriction injury (CCI). PEA is degraded and deactivated preferentially by a lysosomal enzyme NAAA to palmitic acid and ethanolamine. Inhibition of NAAA might be an available drug target for inflammation and pain control by modulating the tissue levels of PEA.

Several types of NAAA inhibitors have been identified so far, among which β-lactones were comprehensively discovered to shed light on the endogenous PEA mediated signaling on inflammation and pain. N-[(3S)-2-oxo-3-oxetanyl]-3-phenylpropanamide [(S)-OOPP] inhibited rat NAAA with a median effective concentration (IC_{50} = 0.42 μM) by normalizing PEA levels in activated inflammatory cells, and reducing tissue reactions to spinal cord trauma with local administration. Recently, a more potent analogue of (S)-OOPP, 5-phenylpentyl N-[(2S,3R)-2-methyl-4-oxo-oxetan-3-yl] carbamate (ARN077), inhibited human NAAA with IC_{50} of approximate 7 nM, normalized FAE levels in inflamed mouse ear skin, and attenuated the hyperalgesia and allodynia in mice which was evoked by carrageenan and sciatic nerve injury with local administration. These compounds contain an unstable β-lactone moiety which is essential for NAAA inhibition, thereby the labile structure hinders their potential application of systemic administration.

In 2014, a series of 3-aminoazetidin-2-ones which the β-lactone ring was replaced by β-lactam was reported by Fiasella, A. et al. as a new class of plasma stable NAAA inhibitors, and exerted systemically activity. In another paper, AM9053 was reported as the first systemically active NAAA inhibitor to increase PEA levels in the colon of mouse models of IBD. But the therapeutic potential and the related mechanism of systemically NAAA inhibition still needs more pharmacological tools and detailed revealing.

Previously, we reported a series of acyl pyrrolidine compounds, such as 1-(2-Biphenyl-4-yl)ethyl-carbonyl pyrrolidine, exhibited good biological stability and inhibited rat NAAA with IC_{50} of 2.12 μM and normalized PEA level accompanied with reduced iNOS and IL-6 inflammatory mediators mRNA express in LPS induced RAW264.7 mice macrophage cells. Herein, we disclose a highly potent and stable NAAA inhibitor, 3-(6-phenylhexanoyl)oxazolidin-2-one (F96), which is suitable for systemic administration. In this report, we described the pharmacological profiles of F96, and its underlying mechanism on inflammatory and neuropathic pain after systemic NAAA inhibition.

Results

**F96 is a selective and stable NAAA inhibitor.** Structural modification based on oxazolidinone imides led us to identify 3-(6-phenylhexanoyl)oxazolidin-2-one (compound F96, Fig. 1a) with a potent NAAA inhibitory activity (IC_{50} for rat NAAA: 269.3 ± 22.4 nM, Fig. 1b, for human NAAA: 268.6 ± 43.8 nM). Incubation of F96 in various concentrations (10 nM-100 μM) in intact HEK-293-rNAAA cells revealed that the IC_{50} of F96 in cells was 419.2 ± 39.6 nM. In addition, F96 exhibited 150-fold selectivity for NAAA over FAAH (IC_{50} for rat FAAH: 42.05 ± 1.92 μM, Fig. 1c) and did not show enough inhibitory activity for MAGL and acid ceramidase (AC) in concentration of 10 μM in vitro (Table 1).

Considering about whether F96 could directly act as a PPAR-α agonist, we engineered 293T cells to express a luciferase reporter gene together with the ligand-binding domain (LBD) of human PPAR-α.

|           | FAAH activity | MGL activity | AC activity | NAAA activity |
|-----------|---------------|--------------|-------------|---------------|
| Vehicle   | 100 ± 3.18    | 100 ± 8.22   | 100 ± 12.31 | 100 ± 3.57    |
| F96 (10 μM) | 80.46 ± 2.74  | 90.07 ± 3.22 | 96.73 ± 8.01| 5.09 ± 0.30   |

Table 1. Effects of F96 on enzyme activities. Values present as mean ± S.E.M.

Figure 1. Characterization of the NAAA inhibitor F96. (a) Structure of compound F96. (b) Concentration-dependent inhibition of extracted recombinant rat NAAA (rNAAA) activity by F96. (c) Concentration-dependent inhibition of extracted recombinant rat FAAH (rFAAH) activity by F96.
fused to the yeast GAL4 DNA-binding domain. In transactivation assay, F96 had no effect on PPAR-α compared with DMSO in all concentrations (Fig. S1a).

We also conducted the PPAR-α competitive binding assay (LanthaScreen® TR-FRET PPAR-α competitive binding assay kit, Life Technologies™) to examine that if F96 could bind to PPAR-α. The results suggested that F96 did not bind to the LBD of PPAR-α even in high doses of 10μM (Fig. 5b). Taken together, F96 is a selective NAAA inhibitor and do not directly active PPAR-α through binding it.

We further evaluated the stability of F96 in various chemical and biological conditions. Results indicated that this compound has excellent stability in either acidic medium (pH 5.0: t1/2 = 1440 min) or basic medium (pH 7.4: t1/2 > 1440 min), which also revealed a considerable metabolic rate when incubated with 80% rat plasma under 37°C physiological conditions (t1/2 = 188 ± 17 min).

Effects of F96 on TPA induced ear edema. TPA induced mice ear edema model is always applied to evaluate the anti-inflammatory effects of lead compounds. Here, we investigated the pharmacological effects of F96 in this model. In consistent with previously reports4, TPA (0.03% in acetone, 10μL) was smeared onto left ears of mice to cause local edema to compare with that of the right vehicle ones (acetone, 10μL). Swelling condition was revealed by H&E assay (Fig. 2a) and ear tissue weight (Fig. 2b; TPA, 35.31 ± 1.78 g vs vehicle, 12.66 ± 0.52 g; P < 0.001). Simultaneous administration of F96 (3–30mg/kg, i.p.) for 3hr reduced ear edema and ear weight (Fig. 2a,b) in a dose dependent manner, and partially normalized PEA and OEA tissue levels (Fig. 2d,e). Moreover, the anti-edema effects of F96 were completely lost in PPAR-α null mice (Fig. 2c). These data suggested that F96 reduced PEA degradation in pathological conditions by inhibiting NAAA, which elevated the endogenous FAEs to activate PPAR-α receptor to exert anti-edema effects on TPA induced mice ear inflammation.

Effects of F96 in acetic acid induced visceral pain. To evaluate whether systemic administration of NAAA inhibitors attenuated behavioral responses to noxious stimuli in rodents, we examined the effects of F96 on nociceptive responses evoked by acetic acid injection. Acetic acid induced writhing was reversed by F96 (10mg/kg, i.p.) (Fig. 3a), which were similar with the analgesic effects of cyclooxynase inhibitor indomethacin at the same dose (10mg/kg, i.p.) (Fig. 3a). Previous reports indicated that PEA might increase the activity of endogenous agonists of CB receptors via ‘entourage effects’28, which we did not completely detect. So, we designed additional experiments to reveal whether CB1 or CB2 was involved in anti-writhing mechanism of F96. As showed in Fig. 3a, the anti-nociceptive effects of F96 (10mg/kg; i.p.) were not blocked by the selective CB1 antagonist Rimonabant (1mg/kg; i.p.) (Fig. 3a), but was blocked by PPAR-α antagonist SR144528 (1mg/kg; i.p.). We further employed PPAR-α−/− mice as a complementary genetic model to confirm the role of PPAR-α in mediating the analgesia of F96. As showed in Fig. 3b, genetic disruption of PPAR-α prevented the nociceptive adaptations caused by NAAA inhibition totally. These findings indicated that pharmacological blockade of NAAA systemically could inhibit acetic acid-induced nociceptive responses through PPAR-α receptor rather than cannabinoid receptors.

Effects of F96 on SNI induced neuropathic pain. We then evaluated the ability of systematic NAAA inhibition to alleviate persistent pain by sciatic nerve injury (SNI). C57BL/6J mice were treated with vehicle, F96 (10mg/kg, i.p.), gabapentin (30mg/kg, i.p.) on the 3rd day and the 7th day after surgery, respectively. Sham surgery was conducted as control group. The withdraw thresholds were investigated at the 3rd and 7th day post-surgery (Fig. 4a,b). Compound F96 indicated significant analgesic effects at the 3rd day and the 7th day after surgery, NAAA inhibition increased pain withdraw thresholds responding to mechanical stimuli on the 7th day post-surgery (Fig. 4c). The antinociceptive effects of F96 (10mg/kg, i.p.) could be blocked by the selective PPAR-α antagonist MK886 (2mg/kg; i.p.) (Fig. 4d), but not CB1, antagonist Rimonabant (1mg/kg; i.p.) nor CB2 antagonist SR144528 (1mg/kg; i.p.). Genetic model experiments revealed that analgesic effects of NAAA inhibition were invalid in PPAR-α−/− mice when compared with that of the wild-type groups (Fig. 4e).

Preliminary toxicity of F96 on zebrafish. Two experiments were performed to preliminarily evaluate the toxicity of F96 by comparing with a commercial nonsteroidal antiinflammatory drug (NSAID) ibuprofen in zebrafish models. The total mortality, hatching number, body length and heartbeats of zebrafish embryos treated with various concentrations of F96 and ibuprofen are shown in Fig. 5. In experiment one, the embryos undergoing early cleavage (two/four celled stages) were exposed to the compounds assessed for 72h. About half of the embryos died when treated with 1mg/L ibuprofen, while almost all embryos survived with the same dose of F96 (Fig. 5a). The survival rate of embryos incubated in 0.3mg/L and 0.1mg/L of F96 were also much higher than ibuprofen. Other parameters such as body length and heartbeats remained nearly the same to controls.
In experiment two, the embryos undergoing 24 h post-fertilization were exposed to the compounds assessed for 72 h. None of the embryos survived in 10 mg/L ibuprofen solution, while all the embryos survived in F96 groups of the same dose (Fig. 5b). In the 0.01 mg/L, 0.1 mg/L and 1 mg/L ibuprofen exposure groups, there was a decrease on the number of hatched larvae. Instead, all the embryos of F96 group hatched in these doses. There was no obvious change in other parameters comparing to control groups. These data suggested that F96 exhibited less toxicity and more safety than ibuprofen.

**Open field assay of F96.** Behavioral studies of mice with F96 treatment in an open field assay revealed that no significant alteration in locomotion was observed even in high dose drug administration. There was no obvious difference between F96 (30, 100, 300 mg/kg, i.p.) and vehicle regarding the total distance, center distance moved in the arena (Fig. 6a,b) for 6 h. High dose administration of F96 (100, 300 mg/kg, i.p.) caused slightly alteration for the time spent in the center area (Fig. 6c) only after treated for 6 h.
Figure 3. F96 suppressed pain responses elicited by intraperitoneal injections of acetic acid in mice. (a) Number of writhing (assessed episodes in 20 min after acetic acid injection) reduced after indomethacin (10 mg/kg, i.p., Gray bars) and F96 (10 mg/kg, i.p., closed bars) administration. PPAR-α antagonist MK886 (2 mg/kg, i.p.) prevented the anti-nociceptive effects of F96. CB1 antagonist Rimonabant (1 mg/kg, i.p.) and CB2 antagonist SR144528 (1 mg/kg, i.p.) did not abolish the analgesic effects of F96. (b) Effects of vehicle (white bars) or F96 (10 mg/kg, i.p., black bars) on acetic acid induced writhing in wild-type 129s mice (+/+) and PPAR-α knockout mice (−/−).

Figure 4. Analgesic effects of F96 in the SNI models. Time-course effect of vehicle (5% PEG/5% Tween-80 in saline, 10 mL/kg, i.p., open squares), F96 (10 mg/kg, i.p., open triangle) and gabapentin (40 mg/kg, i.p., open inverted triangle) on mechanical allodynia in SNI mice at (a) 3rd day post-surgery, and (b) the 7th day post-surgery. Mechanical allodynia were measured 1, 4 and 12 h after treatment. Sham, sham-operated mice (open cycles). (c) Dose-response of F96 (open triangles) on mechanical allodynia in SNI mice 7th day post surgery. Withdraw threshold was assessed 1 h after F96 treatment. Sham, sham-operated mice (open cycle). (d) PPAR-α antagonist MK886 (2 mg/kg, i.p.) prevented the anti-allodynia effects of F96 (10 mg/kg, i.p., closed bars). CB1 antagonist Rimonabant (1 mg/kg, i.p.) and CB2 antagonist SR144528 (1 mg/kg, i.p.) were ineffective. (e) F96 (10 mg/kg, i.p.) increased mechanical paw withdraw threshold in wild-type 129s mice, but not in PPAR-α knockout mice. Results are expressed as mean ± SEM (n = 6–10 each group).
Discussion

It is revealed that activation of CB1 receptor may cause episodes of psychosis and panic in some experiments\(^\text{29}\). Dual FAAH/MAGL inhibition caused potent analgesic effects and also led to hypomotility and catalepsy\(^\text{30}\). NAAA inhibition is supposed to preferentially restoring endogenous PEA to engage PPAR-\(\alpha\) receptors rather than modulating CB receptors to avoid the potential CNS side effects, which was still unexplored \textit{in vivo} for the absence of NAAA knockout mice and stable inhibitors. Here we propose a biological and chemical stable oxazolidinone compound F96 as a novel pharmacological tool to evaluate the detailed functions and mechanisms of systematic NAAA inhibition in inflammatory and neuropathic pain.

In the TPA induced mice ear edema experiment, decreased levels of PEA and OEA were observed in inflammatory conditions, which could be recovered to normal levels by NAAA inhibition with dose dependence. Meanwhile, ear tissues levels of the most important endocannabinoid AEA was not modulated by F96 (Fig. S2). Thus, the first main result of our research is that selective NAAA inhibition systematically restoring PEA and OEA rather than AEA in the inflammatory tissues. F96 could not exert anti-inflammatory and anti-nociceptive effects in PPAR-\(\alpha\) knockout mice, and the pharmacological effects of F96 could also be blocked by MK886, a PPAR-\(\alpha\) antagonist. These data confirmed that the pharmacological response of NAAA inhibition should directly depend upon the activation of PPAR-\(\alpha\).

Previous reports showed that inhibition of FAAH activity by URB937 elevated both substrates of AEA and PEA to cause marked analgesic responses in rodent models of acute and persistent pain\(^\text{31}\). The pharmacological effects of URB937 could be prevented by both the CB1 antagonist (Rimonabant and AM251)
and the PPAR-α antagonist MK886, which was interpreted as two pathways were both involved in the action of FAAH inhibition\(^{31}\). To date, it is widely recognized that PEA, as well as classical endocannabinoids, plays a critical role in pain modulation\(^{3}\). But the role of AEA and PEA in alleviating inflammatory and neuropathic pain respectively was not well distinguished. Ben-shabat et al. described the ‘entourage effect’ of PEA for the first time in 1998, which meant that PEA might act indirectly by increasing the effect of AEA and PEA, in contrast, overexpression of these lipids down-regulates COX-2 levels and activities\(^{34}\). Inhibitors of COX-1 and COX-2 exhibited extensive anti-inflammation and anti-nociceptive effects, but they were always at risk of gastrointestinal hemorrhaging and cardiovascular events. In this study, we compared the NAAA inhibitor with a commercial OTC drug ibuprofen in zebrafish embryos tests. The experimental data suggested that F96 exhibited less toxicity and more safety than ibuprofen, which provided a premise for developing a new candidate in anti-inflammatory and analgesic research field.

**Methods**

**Drugs and reagents.** MK886, SR144528, Rimonabant were purchased from Cayman Chemical (Michigan, USA). Gabapentin and indomethacin were purchased from Sigma-Aldrich (Shanghai, China). All durgs were dissolved in vehicle (5% Tween 80, 5% PEG 400 in saline solution) with various concentrations as indicated.

**Synthesis of F96.** A solution of the 6-phenylhexanoic acid (0.55 mmol) and dimethylformamide (0.05 mL) in CH\(_2\)Cl\(_2\) was added with oxalyl dichloride (0.66 mmol) under nitrogen at 0 °C. The reaction mixture was then stirred at 0 °C under reduced pressure. Then 2-oxazolidone (0.5 mmol) in THF was added slowly in the presence of n–BuLi (0.55 mmol, 0.2 mL hexane) under nitrogen at −78 °C. After being stirred at −78 °C for 10 min, a solution of acid chloride (0.55 mmol) in THF was slowly added. The reaction mixture was stirred at −78 °C for 0.5 h, and allowed to warm slowly to room temperature in 5 h. The reaction was quenched with a saturated NH\(_4\)Cl solution and extracted with EtOAc. The combined organic layers were dried over anhydrous Na\(_2\)SO\(_4\), filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to afford compound F96 as white crystals.

**Ethics statement.** All experiments were carried out in accordance with ‘Guide and Care and Use of Laboratory Animals’ from National Institutes of Health (NIH) and approved by the Animal Care and Use Committees of Xiamen University in China.

**Cells and animals.** HEK293 and RAW264.7 cells were bought from American Type Culture Collection (ATCC, Beijing, China) and were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Hyclone, Beijing, China) supplemented with 10% FBS (Gibco®, Shanghai, China). ICR mice, Kunming mice and C57BL/6j mice were obtained from Shanghai Laboratory Animal Center (Shanghai, China). 129s mice (+/+) and PPAR-α knockout mice (−/−) were from Jackson Laboratory (Bar Harbor, ME, USA). Zebrafish embryos were kind gifts from Prof. Wanshu Hong (School of Life Science, Xiamen University).

**Enzyme activity assay.** The inhibition effects of F96 on enzymes were assessed by enzyme activity assay\(^{21}\). For NAAA activity, 30 μg of recombinant rNAAA proteins were pre-incubated with F96 or vehicle (1% DMSO) at 37°C for 10 min, and then 0.2 μL assay buffer (50 mM phosphate buffer, 0.1% Triton X-100, 3 mM DTT, pH 5.0) containing 25 μM heptadecenoylethanolamide (Avanti Lipids, Alabaster, AL) as substrate was added to co-incubate for further 30 min. For FAAH activity, 30 μg of FAAH proteins were incubated at 37°C for 30 min in Tris buffer (50 mM, pH 8.0) containing fatty acid-free BSA (0.05%) and 25 μM anandamide (Sigma-Aldrich, Shanghai, China) as substrate. For Monoacylglycerol lipase (MAGL) activity, 10 μg of proteins derived from MAGL-overexpressing HEK293 cells were incubated in assay buffer (50 mM Tris, 0.05% fatty acid-free BSA, pH 8.0) with substrate (25 μM 2-oleoylglycerol). Acid ceramidase (AC)activity was measured by incubating 25 μg of proteins which were derived from AC-overexpressing HEK293 cells, with 100 μM N-laurol ceramide as substrate in 100 mM sodium phosphate buffer (0.1% Nonidet P-40, 150 mM NaCl, and 3 mM DTT, pH 4.5) for 30 min at 37°C. The above
reactions were stopped by adding 200μL methanol containing 1 nmol heptadecanoic acid as internal standard.

**Lipid extraction and analysis.** Lipids were extracted from related tissue samples using the modified methods as mentioned\(^5\). Briefly, tissues (20–30 mg) were homogenized by ultrasonication in methanol/water mixture (v/v, 1:1, 1 mL) containing 100 pmoL of heptadecenylethanolamide as internal standard. The homogenate was extracted with 4 mL chloroform and then vortex for 1 min. Lipid layer was separated by centrifugation at 3000 × g for 10 min and then transferred to a clean 10 mL V-bottom glass tube and dried under nitrogen (N\(_2\)) flow. 1 mL chloroform was added to resolve dried spots and solid-phase extraction was eluted by methanol/chloroform (v/v, 1/9). The elution containing FAEs was dried under N\(_2\), and reconstituted in 100 μL methanol for HPLC-MS/MS analysis.

An ABI 3200 Q-Trap mass spectrometer (Applied Biosystems, USA) equipped with 1100-LC system (Agilent, Shanghai, China) was operated during this experiment. The precursor/product ion transitions in multiple reaction monitoring mode (MRM) were used for mass analysis and quantitation. The molecular ions were monitored at m/z 348.00/62.0 for AEA, m/z 326.1/62.0 for OEA, m/z 313.1/62.0 for C17:1 FAE, m/z 300.2/62.0 for PEA, and m/z 287.10/62.0 for 2-AG. The elution containing FAEs was monitored at m/z 379.10/287.10 for 2-AG, and m/z 326.1/62.0 for OEA, m/z 317.10/287.10 for 2-AG, and m/z 317.10/287.10 for 2-AG.

**12-O-Tetradecanoylphorbol-13-acetate (TPA) induced ear edema in mice.** Male C57BL/6J mice, weighting 20–22 g, were provided with food and water ad libitum. TPA (0.03% in acetone, 10 μL) was applied evenly to both sides of the left ears, whereas acetone with the same volume was applied to the matched right ears as control. Simultaneously, F96 (3, 10, 30 μg/kg, dissolved in 5% polyethylene glycol 400 and 5% Tween-80 in saline) was administrated by intraperitoneal injection. Animals were sacrificed after 3 h, and the ears were excised and punched in the same size (diameter = 9 mm). Ear tissues were weighed to assess edema and then divided into 2 parts immediately. One part was immersed in 5% paraformaldehyde solution for H&E assay, and the other part was weighted to quantify tissue FAE levels by HPLC-MS/MS. 129 s mice (+/+) and PPAR-α knockout mice (−/−) (20–22 g) were treated by the same procedure.

**H&E assay.** Fresh mouse ear tissues were fixed in paraformaldehyde at 4°C, and then embedded in paraffin. 5 μm-thick tissue sections were cut by Sliding microtome Leica SM2010 R (Shanghai, China), and were stained with hematoxylin and eosin (H&E) after deparaffinized with xylene. Imaging of stained areas was performed with a light microscopy (Nikon, Shanghai, China).

**Acetic acid-induced writhing in mice.** Male Kunming mice, weighting 20–22 g, were provided with food and water ad libitum. F96 (10 mg/kg, i.p.) was administrated 30 min before the tests. NSAID indomethacin (10 mg/kg, dissolved in 5% polyethylene glycol 400 and 5% Tween-80 in saline) was administrated as a positive control. CB, antagonist Rimonabant (1 mg/kg, dissolved in 5% polyethylene glycol 400 and 5% Tween-80 in saline), CB, antagonist SR144528 (1 mg/kg, dissolved in 5% polyethylene glycol 400 and 5% Tween-80 in saline), and PPAR-α antagonist MK886 (2 mg/kg, dissolved in 5% polyethylene glycol 400 and 5% Tween-80 in saline) were respectively injected into mice abdominal cavity at the same time with F96. After 5 min’s stimulation by acetic acid (0.6% in saline, 10 mL/kg, i.p.), the number of writhing (stretch) responses was counted for the next 20 min. 129 s mice (+/+) and PPAR-α knockout mice (−/−) (20–22 g) were treated by the same procedure.

**Spared nerve injury induced allodia in mice.** The experiments were performed according to the previous reports\(^6\). Simply, male C57BL/6J mice were anesthetized with pentobarbital sodium. The lateral surface of the left thigh proximal to the knee was longitudinally incised to expose the left sciatic nerve and separate the three terminal branches: sural nerve, common peroneal nerve and tibial nerve under a stereomicroscope. The common peroneal and tibial nerves were tightly ligated with suture (6-0 suture), and then were cut by a micro scissor. The wound was sutured, cleaned with 75% ethanol, and covered with sterilized gauze pads. Sham controls involved exposure of the sciatic nerve without any branch lesion. F96, Rimonabant, SR144528 and MK886 were administrated as described in 2.8 at the 3rd and 7th day after surgery. Gabapentin (40 mg/kg, i.p.) was intraperitoneally injected as a positive control. Withdraw threshold was assessed using the automated Dynamic Plantar Aesthesiometer system (Ugo Basile, Comerio, Italy).

**Open field assay.** Male ICR mouse (20–22 g) was placed in the centre of the open field apparatus (length 20 × width 20 × height 30 cm) after F96 treatment (30, 100, 300 mg/kg, i.p.) for 1 h, 3 h and 6 h. Data of mouse motion trails during the first 300 sec of each time period were analyzed. The total distance and centre distance moved in the arena, and the time spent in the center area were monitored by ZH-ZFT type inner open field test system (Huabei Zhenghua Company, China).

**Zebrafish assay.** Zebrafish embryos were used to assess acute toxicity of F96. All tests were performed in triplicate and each set consisted of 10 developing embryos initially. The embryos undergoing early cleavage (two/four celled stages) or 24 h post-fertilization were exposed to different concentrations (0.1, 0.3, 1, 3, 10 μg/L) of F96 or ibuprofen, a commercial NSAID. Compounds were separately
dissolved in dimethyl sulfoxide (DMSO) to make a 10 mM stock solution. The treatment solutions for toxicity tests were obtained by the dilution of the stock solutions with embryo medium. Corresponding zebrafish medium and carrier controls (0.1% DMSO) were maintained. All embryos were put in 96-well plates (one egg per hole) in which the test solutions were renewed every 24 h, and cultured at 28.5°C. Observations were made hourly during the early embryogenesis, thereafter, once every 24 h and up to total 72 h. Dead embryos were removed once detected. Morphologies of embryos/larvae were carefully observed with an inverted microscope and images were captured using an image analyzer. The larvae hatching rate, total mortality, average heartbeats, and body length of all embryos/larvae was recorded on 72 h.

Data analyses and statistics. All statistical analyses were completed by using GraphPad Prism version 5.01. Data were showed as the mean ± SEM and were evaluated by one-way analysis of variance (ANOVA) followed by Dunnett’s test for multiple comparisons. P < 0.05 was considered statistically significant.

References
1. Piomelli, D. & Sasso, O. Peripheral gating of pain signals by endogenous lipid mediators. Nat. Neurosci. 17, 164–174 (2014).
2. Luongo, L., Maione, S. & Di Marzo, V. Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions. Eur. J. Neurosci. 39, 401–408 (2014).
3. LoVerme, J. et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 319, 1051–1061 (2006).
4. Lo Verme, J. et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15–19 (2005).
5. Guardias, M., Estivill-Torrús, G., Goicoechea, C., Bilbao, A. & Rodríguez de Fonseca, F. Analgesic properties of oleylthanolamide (OEA) in visceral and inflammatory pain. Pain 133, 99–110 (2007).
6. Ueda, N., Tsuibo, K. & Uyama, T. Metabolism of endocannabinoids and related N-acyl ethanolamines: canonical and alternative pathways. FEBS J. 280, 1874–1894 (2013).
7. Marini, L., Bartolucci, M. L., Bortolotti, E., Gatto, M. R. & Bonetti, G. A. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J. Orofac. Pain. 26, 99–104 (2012).
8. Keppel Hesselink, J. M. & Kopsky, D. J. Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. J. Pain Res. 6, 239–245 (2013).
9. Calabrò, R. S., Gervasi, G., Marino, S., Mondo, P. N. & Bramanti, P. Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Medicine 11, 781–784 (2010).
10. Taylor, B. R. N-acylthanolamide acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia. Pain 154, 326–327 (2013).
11. Tsuibo, K. et al. Biosynthetic pathways of bioactive N-acyl ethanolamines in brain. CNS Neurol. Disord. Drug Targets 12, 7–16 (2013).
12. Endocannabinoid Research, G. et al. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacol. Res. 61, 321–328 (2010).
13. Costa, B. et al. The dual fatty acid amide hydrolase/TPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol. Res. 61, 537–546 (2010).
14. Sasso, O. et al. Antinociceptive effects of the N-acylthanolamide acid amidase inhibitor ARN077 in rodent pain models. Pain 154, 350–360 (2013).
15. Tsuibo, K., Takezaki, N. & Ueda, N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers. 4, 1914–1925 (2007).
16. Ueda, N., Tsuibo, K. & Uyama, T. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog. Lipid Res. 49, 299–315 (2010).
17. Bandiera, T., Ponzano, S. & Piomelli, D. Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacol. Res. 86, 11–17 (2014).
18. Vitale, R. et al. Synthesis, structure-activity, and structure-stability relationships of 2-substituted-N-(4-oxo-3-oxetanyl) N-acylthanolamine acid amide (NAAA) inhibitors. ChemMedChem. 9, 323–336 (2014).
19. Ponzano, S. et al. Synthetic, Biological Evaluation, and 3D QSAR Study of 2-Methyl-4-oxo-3-oxetanoylcarbamic Acid Esters as N-Acylethanolamine Acid Amidase (NAAA) Inhibitors. J. Med. Chem. 57, 10101–10111 (2014).
20. Fiasella, A. et al. 3-Aminooazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration. ChemMedChem, 9, 1602–1614 (2014).
21. Li, Y. et al. Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds. PLoS One 7, e43023 (2012).
22. Duranti, A. et al. N-(2-oxo-3-oxetanyl)carbamoyl acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. J. Med. Chem. 55, 4832–4836 (2012).
23. Solorzano, C. et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. USA 106, 20966–20971 (2009).
24. Tsuibo, K., Hilligsmann, C., Van de Voorde, S., Lambert, D. M. & Ueda, N. N-cyclohexanecarboxylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amidase hydrolase. Biochem. J. 379, 99–106 (2004).
25. Petrosino, S. et al. Diarylpropionamide is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. Pharmacol. Res. 91, 9–14 (2015).
26. Ribeiro, A. et al. A Potent Systemically Active N-Acyllethanolamide Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. ACS Chem. Biol. (2015).
27. Alhouayek, M. et al. N-Acyllethanolamide-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. FASEB. J. 29, 650–661 (2015).
28. Ho, W. S., Barrett, D. A. & Randall, M. D. ‘Encourage’ effects of N-palmitoylethanolamide and N-oleoylthanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 155, 837–846 (2008).
29. Moreira, F. A., Grieb, M. & Lutz, B. Central side-effects of therapies based on CB 1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 23, 133–144 (2009).
30. Long, I. Z. et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. USA 106, 20270–20275 (2009).
31. Clapper, J. R. et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 13, 1265–1270 (2010).
32. Ben-Shabat, S. et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23–31 (1998).
33. Rouzer, C. A. & Marnett, L. J. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem. Rev. 111, 5899–5921 (2011).
34. Piro, J. R. et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell reports 1, 617–623 (2012).
35. Wu, X. et al. Alteration of endocannabinoid system in human gliomas. J. Neurochem. 120, 842–849 (2012).
36. Yang, L. et al. Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. Int. J. Mol. Sci. 15, 13637–13648 (2014).

Acknowledgements
The authors thank Ms. Jin Fu for help with the design of this research and revise of this manuscript. We also thank Eye Institute of Xiamen University for providing experimental conditions. This study was supported by grants from National Natural Sciences Foundation of China (No. 81373273, 81273371), Xiamen Southern Ocean Research Center Project (No. 14GYY018NF18), and the Fundamental Research Funds for the Central Universities (No. 20720150054).

Author Contributions
L.Y., L.L. and Y.Q. conceived and designed experiments. L.Y., L.L., Y.L., H.C. and L.C. carried out experiments. L.Y., L.C. and L.L. analyzed data and prepared figures. L.Y., L.C., Y.Q. and Y.L. wrote the manuscript. H.C. and G.J. conducted the complementary experiments. D.L. and Z.L. reviewed and revised the manuscript. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yang, L. et al. Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α. Sci. Rep. 5, 13565; doi: 10.1038/srep13565 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/